Corcept Loses Patent Appeal for Korlym, Shares Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy CORT?
Source: stocktwits
- Patent Litigation Outcome: The U.S. Court of Appeals upheld the New Jersey district court's ruling that Corcept failed to prove patent infringement, resulting in significant legal challenges that could impact the company's competitive position in the market.
- Stock Price Reaction: Following the ruling, Corcept's (CORT) shares plummeted by 15%, reflecting investor concerns about the company's future, especially as its Korlym product faces generic competition.
- Market Dynamics: While Corcept's stock declined, Teva Pharmaceuticals (TEVA) saw a slight increase in its share price, indicating a positive market reaction to Teva's victory in the patent dispute, which may enhance its market share.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around CORT stock shifted from 'bearish' to 'bullish' over the past 24 hours, with message volume increasing from 'extremely low' to 'high', indicating investor expectations for a potential rebound.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 46.060
Low
50.00
Averages
91.00
High
121.00
Current: 46.060
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
Corcept Presents New Data on Lifyorli at ASCO 2026
- Clinical Trial Data Presentation: Corcept Therapeutics will present new data from the Phase 3 ROSELLA trial of Lifyorli™ plus nab-paclitaxel for platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting, which is expected to enhance its competitive position in the market.
- FDA Approval of New Drug: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, marking a significant advancement for Corcept in oncology treatment.
- Scarcity of Treatment Options: Approximately 20,000 women in the U.S. are candidates for new therapies for platinum-resistant ovarian cancer each year, and the introduction of Lifyorli will provide new treatment options for these patients, addressing market demand and potentially boosting company performance.
- Collaborative Research Background: The ROSELLA trial was conducted in collaboration with multiple international oncology research organizations, demonstrating Corcept's influence and collaborative capabilities in global oncology research, further solidifying its industry position.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the lead plaintiff deadline on April 21, 2026, and act promptly to protect their rights.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on affected investors and encourages broader participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record, thus investors should carefully select experienced legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the confidence in its relacorilant NDA, failing to disclose FDA concerns regarding clinical evidence, which resulted in investor losses when the truth was revealed.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
Corcept Presents New Data on Lifyorli at ASCO 2026
- Clinical Trial Data Presentation: Corcept Therapeutics will present new data from the Phase 3 ROSELLA trial of Lifyorli™ plus nab-paclitaxel for platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting, which is expected to enhance its competitive position in the market.
- FDA Approval of New Drug: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, marking a significant advancement for Corcept in oncology treatment.
- Scarcity of Treatment Options: Approximately 20,000 women in the U.S. are candidates for new therapies for platinum-resistant ovarian cancer each year, and the introduction of Lifyorli will provide new treatment options for these patients, addressing market demand and potentially boosting company performance.
- Collaborative Research Background: The ROSELLA trial was conducted in collaboration with multiple international oncology research organizations, demonstrating Corcept's influence and collaborative capabilities in global oncology research, further solidifying its industry position.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the lead plaintiff deadline on April 21, 2026, and act promptly to protect their rights.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on affected investors and encourages broader participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record, thus investors should carefully select experienced legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the confidence in its relacorilant NDA, failing to disclose FDA concerns regarding clinical evidence, which resulted in investor losses when the truth was revealed.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
CORT Investors Urged to Act Before April 21 Deadline in Class Action
- Critical Deadline: Hagens Berman reminds investors in Corcept Therapeutics (NASDAQ:CORT) that the deadline to apply as Lead Plaintiff in the securities class action for losses incurred between October 31, 2024, and December 30, 2025, is April 21, 2026, urging prompt submission of loss information to safeguard their rights.
- Allegations Overview: The lawsuit alleges that Corcept concealed significant information regarding its lead drug candidate, relacorilant, as the company publicly emphasized its potential approval while failing to disclose management's private expectations of failure, misleading investors in the process.
- Information Gap: Reed Kathrein, a partner at Hagens Berman, highlighted that the case reveals a
See More
Corcept Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Corcept in the Northern District of California on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025, highlighting significant legal risks and potential liabilities for the company.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the clinical trial results of relacorilant, claiming it provided “powerful support” for FDA approval, while in reality, the FDA raised concerns about the adequacy of clinical evidence, which could undermine the company's credibility and shareholder confidence.
- Stock Price Plunge: Following the announcement of a Complete Response Letter from the FDA on December 31, 2025, Corcept's stock price plummeted from $70.20 to $34.80, a 50.4% drop, reflecting market pessimism regarding the company's future prospects.
- Investor Rights Protection: Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire to understand their legal rights, emphasizing the firm's commitment to protecting investor interests, which may also impact the company's future investment appeal.
See More
